Genetic Variants, Circulating Level of MCP1 with Risk of Chronic Obstructive Pulmonary Disease: A Case-Control Study

References

• Ruvuna L, Sood A. Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med. 2020;41:315–327. doi:10.1016/j.ccm.2020.05.002
   PubMed Web of Science ®Google Scholar
• Diaz-Guzman E, Mannino DM. Epidemiology and prevalence of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35:7–16. doi:10.1016/j.ccm.2013.10.002
   PubMed Web of Science ®Google Scholar
• Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–1788.
   PubMed Web of Science ®Google Scholar
• Yu T, Niu W, Niu H, et al. Chitinase 3-like 1 polymorphisms and risk of chronic obstructive pulmonary disease and asthma in a Chinese population. J Gene Med. 2020;22:e3208. doi:10.1002/jgm.3208
   Web of Science ®Google Scholar
• Henrot P, Prevel R, Berger P, et al. Chemokines in COPD: from implication to therapeutic use. Int J Mol Sci. 2019;20:2785. doi:10.3390/ijms20112785
   Web of Science ®Google Scholar
• Nucera F, Lo Bello F, Shen SS, et al. Role of atypical chemokines and chemokine receptors pathways in the pathogenesis of COPD. Curr Med Chem. 2020. doi:10.2174/0929867327999200819145327
   PubMed Web of Science ®Google Scholar
• Lim SB, Di Lee W, Vasudevan J, et al. Liquid biopsy: one cell at a time. NPJ Precis Oncol. 2019;3:23. doi:10.1038/s41698-019-0095-0
   Web of Science ®Google Scholar
• de Boer WI, Sont JK, van Schadewijk A, et al. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol. 2000;190:619–626. doi:10.1002/(SICI)1096-9896(200004)190:5<619::AID-PATH555>3.0.CO;2-6
   PubMed Web of Science ®Google Scholar
• Chow FY, Nikolic-Paterson DJ, Ma FY, et al. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia. 2007;50:471–480. doi:10.1007/s00125-006-0497-8
   PubMed Web of Science ®Google Scholar
• Labbe K, Danialou G, Gvozdic D, et al. Inhibition of monocyte chemoattractant protein-1 prevents diaphragmatic inflammation and maintains contractile function during endotoxemia. Crit Care. 2010;14:R187. doi:10.1186/cc9295
   Web of Science ®Google Scholar
• Onoda M, Yoshimura K, Aoki H, et al. Lysyl oxidase resolves inflammation by reducing monocyte chemoattractant protein-1 in abdominal aortic aneurysm. Atherosclerosis. 2010;208:366–369. doi:10.1016/j.atherosclerosis.2009.07.036
   Web of Science ®Google Scholar
• Chao J, Donham P, van Rooijen N, et al. Monocyte chemoattractant protein-1 released from alveolar macrophages mediates the systemic inflammation of acute alveolar hypoxia. Am J Respir Cell Mol Biol. 2011;45:53–61. doi:10.1165/rcmb.2010-0264OC
   Web of Science ®Google Scholar
• Lee YG, Jeong JJ, Nyenhuis S, et al. Recruited alveolar macrophages, in response to airway epithelial-derived monocyte chemoattractant protein 1/CCl2, regulate airway inflammation and remodeling in allergic asthma. Am J Respir Cell Mol Biol. 2015;52:772–784. doi:10.1165/rcmb.2014-0255OC
   PubMed Web of Science ®Google Scholar
• Georgakis MK, de Lemos JA, Ayers C, et al. Association of circulating monocyte chemoattractant protein-1 levels with cardiovascular mortality: a meta-analysis of population-based studies. JAMA Cardiol. 2020. doi:10.1001/jamacardio.2020.5392
   Web of Science ®Google Scholar
• Georgakis MK, Malik R, Bjorkbacka H, et al. Circulating monocyte chemoattractant protein-1 and risk of stroke: meta-analysis of population-based studies involving 17 180 individuals. Circ Res. 2019;125:773–782. doi:10.1161/CIRCRESAHA.119.315380
   Web of Science ®Google Scholar
• Li S, Xu Y, Zhang Y, et al. Mendelian randomization analyses of genetically predicted circulating levels of cytokines with risk of breast cancer. NPJ Precis Oncol. 2020;4:25. doi:10.1038/s41698-020-00131-6
   Web of Science ®Google Scholar
• Zhang G, Abuduoufu A, Zhou X, et al. Monocyte chemoattractant protein-1-induced protein in age-related atrial fibrillation and its association with circulating fibrosis biomarkers. Cardiology. 2019;142:244–249. doi:10.1159/000499932
   Web of Science ®Google Scholar
• Talbert EE, Lewis HL, Farren MR, et al. Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naive pancreatic cancer patients. J Cachexia Sarcopenia Muscle. 2018;9:358–368. doi:10.1002/jcsm.12251
   Web of Science ®Google Scholar
• Ksiazek K, Buraczynska M. Association between monocyte chemoattractant protein-1-2518 (A/G) single nucleotide polymorphism and chronic periodontitis in end-stage renal disease patients - a case-control study. Immunol Invest. 2020;49:897–906. doi:10.1080/08820139.2019.1702052
   PubMed Web of Science ®Google Scholar
• Kerget B, Araz O, Erdem HB, et al. The frequency of monocyte chemoattractant protein-1 gene polymorphism in obstructive sleep apnea syndrome. Lung. 2019;197:585–592. doi:10.1007/s00408-019-00256-x
   Web of Science ®Google Scholar
• Martin ES, Schneeberger EE, Aranda FM, et al. The −2518 A/G polymorphism in the monocyte chemoattractant protein 1 gene (MCP-1) is associated with an increased risk of rheumatoid arthritis in Argentine patients. Clin Rheumatol. 2016;35:3057–3061.
   PubMed Web of Science ®Google Scholar
• Tian G, Li X, Li H, et al. Systematic meta-analysis of the association between monocyte chemoattractant protein-1-2518A/G polymorphism and risk of tuberculosis. Genet Mol Res. 2015;14:5501–5510. doi:10.4238/2015.May.25.1
   Web of Science ®Google Scholar
• Mohammad LA, Atef DM, Abul-Saoud AM. Association of monocyte chemoattractant protein 1 (MCP-1) gene polymorphism with lupus nephritis in Egyptian patients. Hum Immunol. 2015;76:724–728. doi:10.1016/j.humimm.2015.09.027
   Web of Science ®Google Scholar
• Bai XY, Li S, Wang M, et al. Association of monocyte chemoattractant protein-1 (MCP-1)-2518A>G polymorphism with susceptibility to coronary artery disease: a meta-analysis. Ann Hum Genet. 2015;79:173–187. doi:10.1111/ahg.12105
   Web of Science ®Google Scholar
• Liu SF, Wang CC, Fang WF, et al. MCP1-2518 polymorphism and chronic obstructive pulmonary disease in Taiwanese men. Exp Lung Res. 2010;36:277–283. doi:10.3109/01902140903575989
   PubMed Web of Science ®Google Scholar
• Bai J, Song H, Cai C, et al. The association of monocyte chemotactic protein-1 and CC chemokine receptor 2 gene variants with chronic obstructive pulmonary disease. DNA Cell Biol. 2012;31:1058–1063. doi:10.1089/dna.2011.1520
   Web of Science ®Google Scholar
• Xu Z, Li J, Yang H, et al. Association of CCL2 gene variants with osteoarthritis. Arch Med Res. 2019;50:86–90. doi:10.1016/j.arcmed.2019.05.014
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang S, Wu X, et al. Correlation between MCP-1-2518A/G polymorphism and the risk of Alzheimer’s disease. J Neural Transm. 2018;125:1781–1786. doi:10.1007/s00702-018-1936-7
   Web of Science ®Google Scholar
• Ma G, Yang J, Zhao B, et al. Correlation between CCL2, CALCA, and CX3CL1 gene polymorphisms and chronic pain after cesarean section in Chinese Han women: a case control study. Medicine. 2019;98:e16706. doi:10.1097/MD.0000000000016706
   Web of Science ®Google Scholar
• Lonsdale J, Thomas J, Salvatore M, et al. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45:580–585. doi:10.1038/ng.2653
   PubMed Web of Science ®Google Scholar